A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Study sponsor: Edgewise Therapeutics, Inc. · EWTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-12Estimated
Enrollment · participants90Estimated
Source updated2026-10-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.